ERBB2, erb-b2 receptor tyrosine kinase 2, 2064

N. diseases: 995; N. variants: 85
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.400 Biomarker disease BEFREE The Z<sub>HER2:V2</sub>-pemetrexed conjugate could inhibit tumor growth of HER2-positive lung adenocarcinoma and may have the potential to become a targeted drug for lung cancer. 30578135 2020
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.400 Biomarker disease BEFREE To assess antigen reactivity, <sup>89</sup>Zr-DFO-trastuzumab was evaluated using the Lindmo method and tested in PET/CT imaging of mouse models of human epidermal growth factor receptor 2-positive or -negative lung cancer. 30442753 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.400 GeneticVariation disease BEFREE Patients with lung cancer and HER2 mutations developed more brain metastases on treatment than patients with KRAS mutations (28% vs 8%; hazard ratio [HR], 5.2; P < .001) and trended more than patients with EGFR mutations (28% vs 16%; HR, 1.7; P = .06). 31469421 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.400 AlteredExpression disease BEFREE No EGFR mutations were detected in BC tissue and no HER2 expression was detected in LC samples. 30799393 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.400 GeneticVariation disease BEFREE We examined changes in CTC numbers and morphology early after targeting therapy in EGFR-mutated PC-9 human lung cancer and HER2-gene amplified GLM-1 gastric cancer mouse CTC models using a cytology-based semi-automated CTC detection platform. 31519570 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.400 Biomarker disease BEFREE Overlapping with ERBB2-associated human lung cancer genes further identified those ERBB2 downstream players potentially conserved in human and mouse lung tumors. 31248101 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.400 GeneticVariation disease BEFREE The variable responses to anti-HER2 therapies in these patients prompt us to examine impact of <i>HER2</i> variants and co-mutations on responses to anti-HER2 treatments in lung cancer. 31748336 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.400 GeneticVariation disease BEFREE Germline mutations in EGFR and erb-b2 receptor tyrosine kinase 2 (ERBB2) have been previously reported in lung cancers that may be associated with genetic susceptibility to lung cancer. 30610926 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.400 GeneticVariation disease BEFREE Consistent with this, a G660D germline mutant lung cancer patient showed remarkable clinical response to HER2 blockade. 30449325 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.400 GeneticVariation disease BEFREE PI3KCA activating mutations were associated with ERBB2 mutations in 12.4% of cases mainly in breast and lung cancer. 29941010 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.400 Biomarker disease BEFREE The present study involves ligand-based pharmacophore modeling of various kinases, including EGFR (T790 M), cMET, ErbB2, FGFR and ALK, which are well established targets of normal as well resistant lung cancer. 30343450 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.400 GeneticVariation disease BEFREE Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study. 30527195 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.400 GeneticVariation disease BEFREE Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations. 29532558 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.400 GeneticVariation disease BEFREE This is the first radiogenomics study of HER2 mutations in lung cancer. 29906786 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.400 Biomarker disease BEFREE Results suggested that the conjugate exhibited selective antiproliferative activity in HER2-overexpressing breast and lung cancer cell lines and was able to block HER2:HER3 heterodimerization. 30314880 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.400 GeneticVariation disease BEFREE The Lung Cancer Mutation Consortium (LCMC) is a multi-institutional effort to identify and treat oncogenic driver events in patients with lung adenocarcinomas.<b>Experimental Design:</b> Sixteen U.S. institutions enrolled 1,367 patients with lung cancer in LCMC2; 904 were deemed eligible and had at least one of 14 cancer-related genes profiled using validated methods including genotyping, massively parallel sequencing, and IHC.<b>Results:</b> The use of targeted therapies in patients with <i>EGFR, ERBB2,</i> or <i>BRAF</i> p.V600E mutations, <i>ALK, ROS1</i>, or <i>RET</i> rearrangements, or <i>MET</i> amplification was associated with a survival increment of 1.5 years compared with those with such mutations not receiving targeted therapy, and 1.0 year compared with those lacking a targetable driver. 29217530 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.400 GeneticVariation disease BEFREE Activating EGFR mutations, HER2, and HER3 are implicated in lung cancer; however, with the exception of EGFR gene amplification in lung adenocarcinoma harboring EGFR mutations, their involvement in disease progression during the early stages is poorly understood. 29473311 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.400 AlteredExpression disease BEFREE Among these, a symmetrical cyclic peptidomimetic (compound 18) exhibited antiproliferative activity in HER2-overexpressing lung cancer cell lines with IC<sub>50</sub> values in the nanomolar concentration range. 29436155 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.400 GeneticVariation disease BEFREE In contrast, afatinib and neratinib were predicted to be more effective than other inhibitors for the A775_776insYVMA mutation, the most frequent <i>ERBB2</i> mutation in lung cancer. 29967253 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.400 GeneticVariation disease BEFREE Highly sensitive detection of a HER2 12-base pair duplicated insertion mutation in lung cancer using the Eprobe-PCR method. 28152008 2017
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.400 GeneticVariation disease BEFREE Lung cancer of never smokers exhibited significantly higher ctDNA mutation rates as well as higher EGFR and ERBB2 mutations than ever smokers. 28472989 2017
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.400 Biomarker disease BEFREE HER2 should be in the clinical genotyping of lung cancer, so patients may benefit from HER2-targeted therapy. 27008586 2017
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.400 Biomarker disease BEFREE This trial will provide information on whether T-DM1 monotherapy is effective against HER2+ lung cancer. 27497829 2017
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.400 GeneticVariation disease BEFREE Integrated Exploitation of the Structural Diversity Space of Chemotherapy Drugs to Selectively Inhibit HER2 T798M Mutant in Lung Cancer. 27696725 2017
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.400 Biomarker disease BEFREE The peptidomimetic (Cyclo(1,10)PpR (<i>R</i>) Anapa-FDDF-(<i>R</i>)-Anapa)R, compound 18) was shown to exhibit antiproliferative activity with an IC<sub>50</sub> of 194 nM in HER2-expressing breast cancer cell lines and 18 nM in lung cancer cell lines. 29088782 2017